Evidence map›Paper›PMID 28663854›Full record

ArticleBiomedical optics express2017

The ecosystem that powered the translation of OCT from fundamental research to clinical and commercial impact [Invited].

Eric A Swanson, James G Fujimoto

Registry-linked trialAbstract read
In one paragraph

Article in Biomedical optics express, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06685783 (Vis-Rx Prime Micro-Imaging Catheter Clinical Evaluation Study), which is not on this map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06685783 completednot on this mapstarted 2024, after this paper: background citation

Vis-Rx Prime Micro-Imaging Catheter Clinical Evaluation Study

TypeobservationalSponsorGentuity, LLCRan2024 to 2025Enrolled34ConditionsCoronary Artery Disease
3 · Its place in the literature

Who cites it

60 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Guide to dynamic OCT data analysis.Biomedical optics express · 2025
    Article
  9. Article
  10. Mobile Robotic Optical Coherence Tomography System for Ophthalmic Imaging in Clinical Environments.... International Symposium on Medical Robotics. International Symposium on Medical Robotics · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. QnAs with James G. Fujimoto, David Huang, and Eric A. Swanson: Winners of the 2023 Lasker~DeBakey Clinical Medical Research Award.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eric A SwansonDepartment of Electrical Engineering & Computer Science and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA, USA.
James G FujimotoDepartment of Electrical Engineering & Computer Science and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA, USA.

Funding

Novel Optical Diagnostics with Optical Coherence TomographyR01EY011289 · NEI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI JAMES G FUJIMOTO · 1995 to 2026
$9.5M
OPTICAL BIOPSY USING OPTICAL COHERENCE TOMOGRAPHYR01CA075289 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FUJIMOTO, JAMES G, MASHIMO, HIROSHI · 1997 to 2018
$4.8M
NCI NIH HHS R01 CA075289NEI NIH HHS R01 EY011289
6 · The paper itself

Abstract

25 years is a relatively short period of time for a medical technology to become a standard of care impacting the treatment of millions of people every year. Yet 25 years ago there were no OCT companies, no OCT products, no OCT markets, and only one journal article published using the term OCT (optical coherence tomography). OCT has had a tremendous scientific, clinical, and economic impact on society. Today, it is estimated that there are ~30 Million OCT imaging procedures performed worldwide every year and the OCT system market is approaching $1B per year. OCT has helped diagnose patients with retinal disease at early treatable stages, preventing or greatly reducing irreversible vision loss. The technology has facilitated pharmaceutical development and contributed to fundamental understanding of disease mechanisms in multiple fields. The invention and translation of OCT from fundamental research to daily clinical practice would not have been possible without a complex ecosystem involving interaction among physics, engineering, and clinical medicine; government funding of fundamental and clinical research; collaborative and competitive research in the academic sector; entrepreneurship and industry; addressing real clinical needs; harnessing the innovation that occurs at the boundaries of disciplines; and economic and societal impact. This invited review paper discusses the translation of OCT from fundamental research to clinical practice and commercial impact, as well as describes the ecosystem that helped power OCT to where it is today and will continue to drive future advances. While OCT is an example of a technology that has had a powerful impact, there are many biomedical technologies which are poised for translation to clinical practice, and it is our hope that highlighting this ecosystem will help accelerate their translation and clinical impact.

Indexed as

(170.3880) Medical and biological imaging(170.4500) Optical coherence tomography

Identifiers

PMID28663854
PMCPMC5480569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.